NQO1 and polycystic ovary syndrome: NQO1 is inhibited by dicoumarol, and more specific next‐generation NQO1‐inhibitors are now available (Figure 3).44 Therefore, the preclinical testing of such compounds for the treatment of EC and prevention of future EC in PCOS is warranted.